Cardiovascular diseases remain a leading cause of morbidity and mortality worldwide. This review highlights ten promising antihypertensive drug candidates with the potential to address pulmonary arterial hypertension (PAH), resistant hypertension and uncontrolled hypertension. Aprocitentan, developed by Janssen NYSE:JNJ) and Idorsia (SIX:IDIA), is an experimental oral drug designed to treat resistant hypertension. As a dual endothelin…
CinCor stock surges after AstraZeneca announces plan to buy company for up to $1.8B
AstraZeneca (LON:AZN) announced it had reached an agreement to acquire CinCor Pharma (Nasdaq:CINC). After announcing the proposed deal, CinCor’s share price jumped 144% to $28.74. AstraZeneca has agreed to a tender offer to acquire outstanding shares of CinCor for $26 per share, or $1.3 billion. CinCor specializes in developing therapies for hypertension and chronic kidney…
CinCor’s COO has a mission to transform hypertension treatment
The clinical-stage biopharma CinCor is developing baxdrostat, a highly selective, oral small molecule inhibitor of aldosterone synthase, for hypertension. Catherine Pearce, chief operating officer and co-founder of CinCor, acknowledges that the company has received criticism for its plan to bring a new drug into the highly genericized blood pressure control market. “The reality is that…